Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1
I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova · 1991 · SU1674849A1 · patent family 21434935
Published 1991-09-07.
This source appears in the Thymalin–Dalargin evidence review. A single-agent experiment, comparative study or patent alternative is not automatically a combined-treatment trial.
Reported patent results
Reported findings
The patent chose alternative peptides for opposing lymphocyte profiles. Case immune measures changed during combined care; no simultaneous Thymalin–Dalargin regimen was established.
Three disclosed individual psoriasis cases, each receiving a different peptide alongside photochemotherapy; these are not controlled treatment groups.
| Measure | Result | Comparison, timing and statistics |
|---|---|---|
| Alternative-treatment examples | Dalargin case B cells 10%→20%; Thymalin case 32%→13%; T-activin case 28.6%→14% | One selected patient per peptide, with photochemotherapy; changes are not comparative treatment effects |
| Dalargin case: immune measures | T-suppressor index 9%→25%; T-helper index 71%→55% | Example 2; B cells 10%→20%; historical subset methods are not modern Treg measurements |
| Thymalin case: immune measures | T-suppressor index 33%→30%; T-helper index 35%→57% | Example 3; B cells 32%→13% |
| T-activin case: immune measures | T-suppressor index 40%→34%; T-helper index 31.4%→52% | Example 1; B cells 28.6%→14% |
| Clinical course in selected cases | Discharge reported on day 19 with Dalargin and day 21 with Thymalin or T-activin | Individual clinical descriptions; no matched control or causal days-saved estimate |
| Russian-text peptide schedules | Dalargin 1 mg intramuscularly twice daily for 5 days; Thymalin 5 mg intramuscularly once daily for 4 days; or T-activin 50 µg subcutaneously daily for 5 days | Alternative historical treatments with photochemotherapy, not a combined or current prescribing regimen |
| Translation and extraction gaps | English abstract mistranslates T-activin as 50 mg; one Thymalin case mistranslates frequency as four times daily | Russian text and course totals specify 50 µg and once daily, respectively. Patent PDF and aggregate comparison table not recovered. |
Three selected patent cases: before → after
| Historical immune measure | Dalargin, example 2 | Thymalin, example 3 | T-activin, example 1 |
|---|---|---|---|
| B-lymphocytes (%) | 10→20 | 32→13 | 28.6→14 |
| T-suppressor index (%) | 9→25 | 33→30 | 40→34 |
| T-helper index (%) | 71→55 | 35→57 | 31.4→52 |
Case descriptions, not study-arm means; n=1 selected patient per preparation. Photochemotherapy was concurrent. Historical subset labels do not establish modern regulatory-T-cell phenotypes.
This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
Source for the extracted data ↗ · Checked 2026-11-08
Patent claims and provenance
Use. Selects Dalargin, Thymalin or T-activin as alternatives according to historical lymphocyte profiles, alongside photochemotherapy. Not a claim to simultaneous Thymalin–Dalargin administration.
Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
- Publication
- SU1674849A1 ↗ · 1991-09-07
- Earliest priority / filing
- 1989-03-20 / 1989-03-20
- Original applicant / assignee
- Irkutsk State Medical Institute
- Indexed status
- Current legal status not established from this indexed record; official register not reviewed · checked 2026-11-08
- Patent family
- 21434935 · family publications are related filings, not independent studies.
Original title, inventors and related publications
Способ лечения псориаза
Inventors: I. O. Malova; R. G. Skvortsova; N. P. Kuznetsova.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Selected case reports with photochemotherapy and historical immune assays; no controlled pair trial or isolated peptide effect. Russian dose/frequency statements are distinguished from mistranslated English text.
- This patent supports an early hypothesis of immune-profile-dependent peptide selection, not Thymalin–Dalargin synergy. The before/after changes cannot isolate peptide effects from photochemotherapy, natural fluctuation or selection of favorable cases.
- Patents record claimed inventions and supporting disclosures. Publication or grant does not establish clinical efficacy, safety or marketing approval. Members of one patent family and related journal reports can describe the same experiments.
- Status labels are Google Patents index snapshots for the displayed publication or application; the record gives its source-check date. Official registers and every national family member have not been independently checked. These labels do not establish freedom to operate.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Document format: Original patent text and indexed metadata
Review depth: Claims, selected reported findings and limitations reviewed; supporting experiments not comprehensively appraised.
Related-report group: patent-family-21434935. Reports in this group are not assumed to be independent trials.
Source access and review scope
Original patent publication accessed through Google Patents. Claims, selected reported findings and source limitations checked. The results section identifies the examples, tables and any numerical extraction gaps. No complete experimental audit, prosecution review or legal claim construction was performed.
Recorded source-check date: 2026-11-08. This date does not imply a completed systematic review.
Source type: Patent publication
Citation and original source
Original source: I. O. Malova, R. G. Skvortsova, N. P. Kuznetsova. Immune-profile-directed peptide selection with psoriasis photochemotherapy — SU1674849A1 SU1674849A1 · patent family 21434935 1991.
Molekul research summary: https://molekul.io/research/patent-su1674849a1. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entryRelated compound profiles
Dalargin
A Soviet synthetic opioid hexapeptide investigated in cytoprotection, stress, hypoxia, ischemia and trauma. Its enkephalin lineage is distinct from organ-derived peptide bioregulators; historical proposals and laboratory effects are not established clinical indications.
Thymalin
Thymus-derived peptide mixture with historical Russian studies in autoimmune cytopenias and thyroiditis, alongside other treatments. It is distinct from synthetic Thymogen and Thymodepressin.
Tactivin
Thymus-derived polypeptide preparation studied as an immune adjunct and in animal learning models. Clinical findings include a reported infection reduction in leukemia and a neutral melanoma comparison.